Heron Therapeutics Files 8-K Report

TL;DR

HERON THERAPEUTICS FILES 8-K: REG FD DISCLOSURE & FINANCIALS UPDATE.

AI Summary

On July 2, 2024, Heron Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific financial figures or material events were detailed in the provided excerpt, but it indicates a standard reporting event for the company.

Why It Matters

This filing is a routine disclosure by Heron Therapeutics, Inc. to the SEC, providing updates on financial statements and exhibits as required by regulations.

Risk Assessment

Risk Level: low — This filing is a standard procedural disclosure and does not appear to contain any new material information that would immediately impact the company's risk profile.

Key Numbers

• 0000818033 — Central Index Key (Unique identifier for Heron Therapeutics, Inc.)
• 001-33221 — Commission File Number (SEC file number for Heron Therapeutics, Inc.)
• 942875566 — IRS Employer Identification No. (Tax identification number for Heron Therapeutics, Inc.)

Key Players & Entities

• Heron Therapeutics, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• San Diego, CA (location) — Principal executive offices
• AP Pharma Inc (company) — Former company name
• Advanced Polymer Systems Inc (company) — Former company name

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share HRTX The Nasdaq Capital M

Filing Documents

• hrtx-20240702.htm (8-K) — 47KB
• hrtx-ex99_1.htm (EX-99.1) — 20KB
• 0000950170-24-080026.txt ( ) — 192KB
• hrtx-20240702.xsd (EX-101.SCH) — 30KB
• hrtx-20240702_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On July 2, 2024, Heron Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has acknowledged the receipt of the Company's Prior Approval Supplement application for ZYNRELEF (bupivacaine and meloxicam) extended-release solution Vial Access Needle, as further described in the press release. The FDA has assigned a Prescription Drug User Fee Act goal date of September 23, 2024. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference in this Item 7.01. As provided in General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall such information or Exhibit 99.1 be deemed to be incorporated by reference in any filing under the Securities Act, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated July 2, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Heron Therapeutics, Inc. Date: July 2, 2024 /s/ Ira Duarte Ira Duarte Executive Vice President, Chief Financial Officer